IN2014DN06781A - - Google Patents

Download PDF

Info

Publication number
IN2014DN06781A
IN2014DN06781A IN6781DEN2014A IN2014DN06781A IN 2014DN06781 A IN2014DN06781 A IN 2014DN06781A IN 6781DEN2014 A IN6781DEN2014 A IN 6781DEN2014A IN 2014DN06781 A IN2014DN06781 A IN 2014DN06781A
Authority
IN
India
Prior art keywords
salt
salts
cushing
aromatase
pyrrolo
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Sutton
Eric Loeser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47604250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN06781(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN06781A publication Critical patent/IN2014DN06781A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN6781DEN2014 2012-01-17 2013-01-15 IN2014DN06781A (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261587280P 2012-01-17 2012-01-17
PCT/US2013/021521 WO2013109514A1 (en) 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor

Publications (1)

Publication Number Publication Date
IN2014DN06781A true IN2014DN06781A (no) 2015-05-22

Family

ID=47604250

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6781DEN2014 IN2014DN06781A (no) 2012-01-17 2013-01-15

Country Status (41)

Country Link
US (2) US9334276B2 (no)
EP (1) EP2804863B1 (no)
JP (1) JP5749410B2 (no)
KR (2) KR20140093726A (no)
CN (1) CN104039793B (no)
AP (1) AP2014007762A0 (no)
AR (1) AR089728A1 (no)
AU (1) AU2013209952B2 (no)
BR (1) BR112014017260A8 (no)
CA (1) CA2863339C (no)
CL (1) CL2014001863A1 (no)
CO (1) CO7000775A2 (no)
CR (1) CR20140345A (no)
CU (1) CU20140086A7 (no)
CY (1) CY1117914T1 (no)
DK (1) DK2804863T3 (no)
EA (1) EA026232B1 (no)
ES (1) ES2564143T3 (no)
GT (1) GT201400155A (no)
HK (1) HK1198536A1 (no)
HR (1) HRP20160178T1 (no)
HU (1) HUE026984T2 (no)
IL (1) IL233541B (no)
IN (1) IN2014DN06781A (no)
JO (1) JO3137B1 (no)
MA (1) MA35858B1 (no)
MX (1) MX2014008686A (no)
NZ (1) NZ626277A (no)
PE (1) PE20142358A1 (no)
PH (1) PH12014501638A1 (no)
PL (1) PL2804863T3 (no)
RS (1) RS54589B1 (no)
SG (1) SG11201404061YA (no)
SI (1) SI2804863T1 (no)
SM (1) SMT201600083B (no)
TN (1) TN2014000256A1 (no)
TW (1) TWI609869B (no)
UA (1) UA114803C2 (no)
UY (1) UY34576A (no)
WO (1) WO2013109514A1 (no)
ZA (1) ZA201404314B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2523731T (pt) * 2010-01-14 2019-01-21 Novartis Ag Uso de um agente modificador de hormona adrenal
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
BR112016030243B1 (pt) * 2014-07-07 2023-04-11 Recordati Ag Formas de dosagem farmacêuticas, seu processo de preparação, e usos de celulose microcristalina
US10556869B2 (en) * 2015-01-29 2020-02-11 Novartis Ag Process for the production of condensed imidazolo derivatives
US20160287565A1 (en) * 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
WO2018078049A1 (en) * 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
KR102506380B1 (ko) * 2016-10-27 2023-03-03 다미안 파르마 에이쥐 알도스테론 합성효소 저해제
CA3097281A1 (en) 2018-05-03 2019-11-07 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1315449A (en) * 1918-11-15 1919-09-09 Frank B Yingling Shaper-feed.
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5066656A (en) 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
MTP1076B (en) 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
DE69330557T2 (de) 1992-01-27 2002-06-20 Janssen Pharmaceutica Nv Pyrroloimidazolyl und imidazopyridinyl substituierte 1h-benzimidazolderivate als aromatase inhibitoren
PT1565463E (pt) * 2002-11-18 2008-09-10 Novartis Ag Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
RU2009127642A (ru) 2006-12-18 2011-01-27 Новартис АГ (CH) 1-замещенные производные имидазола и их применение в качестве ингибиторов альдостеронсинтазы
CN102666535B (zh) 2009-11-30 2015-02-25 诺华股份有限公司 作为醛固酮合酶抑制剂的咪唑衍生物
PT2523731T (pt) * 2010-01-14 2019-01-21 Novartis Ag Uso de um agente modificador de hormona adrenal

Also Published As

Publication number Publication date
WO2013109514A1 (en) 2013-07-25
PH12014501638B1 (en) 2014-10-13
EA201491374A1 (ru) 2014-12-30
IL233541B (en) 2018-12-31
ZA201404314B (en) 2015-08-26
EP2804863B1 (en) 2015-12-02
TWI609869B (zh) 2018-01-01
SMT201600083B (it) 2016-04-29
TN2014000256A1 (en) 2015-09-30
CO7000775A2 (es) 2014-07-21
HK1198536A1 (en) 2015-05-15
JP5749410B2 (ja) 2015-07-15
CU20140086A7 (es) 2014-12-26
HRP20160178T1 (hr) 2016-03-25
EA026232B1 (ru) 2017-03-31
AP2014007762A0 (en) 2014-07-31
RS54589B1 (en) 2016-08-31
MA35858B1 (fr) 2014-12-01
AU2013209952A1 (en) 2014-07-24
SI2804863T1 (sl) 2016-05-31
CA2863339A1 (en) 2013-07-25
GT201400155A (es) 2017-09-28
CN104039793B (zh) 2017-05-10
CY1117914T1 (el) 2017-05-17
PH12014501638A1 (en) 2014-10-13
MX2014008686A (es) 2014-08-27
PE20142358A1 (es) 2015-01-30
IL233541A0 (en) 2014-08-31
TW201335161A (zh) 2013-09-01
CN104039793A (zh) 2014-09-10
AU2013209952B2 (en) 2016-09-01
BR112014017260A2 (pt) 2017-06-13
PL2804863T3 (pl) 2016-06-30
CL2014001863A1 (es) 2014-11-07
CA2863339C (en) 2021-03-23
ES2564143T8 (es) 2020-11-18
JO3137B1 (ar) 2017-09-20
JP2015503627A (ja) 2015-02-02
US9334276B2 (en) 2016-05-10
SG11201404061YA (en) 2014-08-28
UY34576A (es) 2013-09-02
ES2564143T3 (es) 2016-03-18
NZ626277A (en) 2015-10-30
HUE026984T2 (en) 2016-08-29
KR20140141687A (ko) 2014-12-10
BR112014017260A8 (pt) 2017-07-04
CR20140345A (es) 2014-09-09
US20160176883A1 (en) 2016-06-23
AR089728A1 (es) 2014-09-10
UA114803C2 (uk) 2017-08-10
US20140364470A1 (en) 2014-12-11
KR20140093726A (ko) 2014-07-28
EP2804863A1 (en) 2014-11-26
DK2804863T3 (en) 2016-03-07

Similar Documents

Publication Publication Date Title
IN2014DN06781A (no)
HK1244483A1 (zh) (s)-n-(5 - ((r)-2-(2,5-二氟苯基)吡咯烷-1-基) - 吡唑並[1,5-a ]嘧啶-3-基)-3-羥基吡咯烷-1-甲酰胺硫酸氫鹽
HRP20182007T1 (hr) Derivati 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina za liječenje respiratornih bolesti
IL235659A0 (en) History of 3, 4 - dihydro -2h - pyrido [1, 2 - a] pyrazine - 1,2,1] 6 converted diones used to treat (among others) Alzheimer's disease
MX370852B (es) Sal (es) de dimetil-amida del ácido 7-ciclopentil-2- (5-piperazin-1-il-piridin-2-il-amino) -7h-pirrolo- [2, 3-d]-pirimidin-6-carboxílico y procesos para su elaboración.
LT3808749T (lt) Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai vėžinių susirgimų gydymui
PH12015500988B1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
IN2014DN07384A (no)
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
GEP20156285B (en) Compounds and compositions as trk inhibitors
PH12015501586A1 (en) 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
HK1177207A1 (en) 5-oxo-5, 8-dihydropyrido [2, 3-d]pyrimidine derivatives as camkii kinases inhibitors for the treatment of cardiovascular diseases camkii 5--58-[23-d]
TN2013000377A1 (en) Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia
MX361933B (es) Sal y formas polimorficas de (3r,4s)-l-((4-amino-5h-pirrolo [3,2-d]pirimidin-7-il)metil)-4 (metiltiometil)pirodin-3-ol(mtdia).
TN2013000483A1 (en) Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
TN2013000146A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof